{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:12:13Z","timestamp":1794355933883,"version":"4.9.0"},"reference-count":46,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JP Moulton Charitable Foundation"},{"name":"Cure Parkinson's Trust"},{"name":"Sheffield NIHR Biomedical Research Centre"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,6,18]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There are no disease-modifying treatments for Parkinson\u2019s disease (PD). We undertook the first drug screen in PD patient tissue and idntified ursodeoxycholic acid (UDCA) as a promising mitochondrial rescue agent. The aims of this trial are to determine safety and tolerability of UDCA in PD at 30\u2009mg\/kg, confirm the target engagement of UDCA, apply a novel motion sensor-based approach to quantify disease progression objectively, and estimate the mean effect size and its variance on the change in motor severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This is a phase II, two-centre, double-blind, randomised, placebo-controlled trial of UDCA at a dose of 30\u2009mg\/kg in 30 participants with early PD. Treatment duration is 48 weeks, followed by an 8-week washout phase. Randomisation is 2:1, drug to placebo. Assessments are performed at baseline, week 12, 24, 36, 48 and 56. The primary outcome is safety and tolerability. Secondary outcomes will compare the change between baseline and week 48 using the following three approaches: the Movement Disorders Society Unified Parkinson\u2019s Disease Rating Scale Part 3 in the practically defined \u2018OFF\u2019 medication state; confirmation of target engagement, applying\n                      <jats:sup>31<\/jats:sup>\n                      Phosphorus MR Spectroscopy to assess the levels of ATP and relevant metabolites in the brain; and objective quantification of motor impairment, using a validated, motion sensor-based approach. The primary outcome will be reported using descriptive statistics and comparisons between treatment groups. For each secondary outcome, the change from baseline will be summarised within treatment groups using summary statistics and appropriate statistical tests assessing for significant differences. All outcomes will use an intention-to-treat analysis population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This trial has been approved by the East of England \u2013 Cambridgeshire and Hertfordshire Research Ethics committee. Results will be disseminated in peer-reviewed journals, presentations at scientific meetings and to patients in a lay-summary format.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT03840005\">NCT03840005<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-038911","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T01:48:27Z","timestamp":1596678507000},"page":"e038911","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson\u2019s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03840005","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-7847","authenticated-orcid":false,"given":"Thomas","family":"Payne","sequence":"first","affiliation":[{"name":"Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK"},{"name":"NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Sassani","sequence":"additional","affiliation":[{"name":"Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-6286","authenticated-orcid":false,"given":"Ellen","family":"Buckley","sequence":"additional","affiliation":[{"name":"NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK"},{"name":"Institute for In Silico Medicine, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Moll","sequence":"additional","affiliation":[{"name":"NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Anton","sequence":"additional","affiliation":[{"name":"NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK"},{"name":"Academic Unit of Radiology, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Appleby","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Maru","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Taylor","sequence":"additional","affiliation":[{"name":"Statistical Services Unit, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisdair","family":"McNeill","sequence":"additional","affiliation":[{"name":"Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Hoggard","sequence":"additional","affiliation":[{"name":"Academic Unit of Radiology, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mazza","sequence":"additional","affiliation":[{"name":"Institute for In Silico Medicine, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain D","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Academic Unit of Radiology, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Foltynie","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3149-0252","authenticated-orcid":false,"given":"O","family":"Bandmann","sequence":"additional","affiliation":[{"name":"Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK"},{"name":"NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"2025121600280921000_10.8.e038911.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61393-3"},{"key":"2025121600280921000_10.8.e038911.2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000247740.47667.03"},{"key":"2025121600280921000_10.8.e038911.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61010-2"},{"key":"2025121600280921000_10.8.e038911.4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt224"},{"key":"2025121600280921000_10.8.e038911.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001905"},{"key":"2025121600280921000_10.8.e038911.6","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-014-9043-8"},{"key":"2025121600280921000_10.8.e038911.7","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-012-8295-4"},{"key":"2025121600280921000_10.8.e038911.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2009.09.055"},{"key":"2025121600280921000_10.8.e038911.9","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3928-08.2008"},{"key":"2025121600280921000_10.8.e038911.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11293-X"},{"key":"2025121600280921000_10.8.e038911.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.12.023"},{"key":"2025121600280921000_10.8.e038911.12","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198427020-00001"},{"key":"2025121600280921000_10.8.e038911.13","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181c47569"},{"key":"2025121600280921000_10.8.e038911.14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.3.181"},{"key":"2025121600280921000_10.8.e038911.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31585-4"},{"key":"2025121600280921000_10.8.e038911.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"2025121600280921000_10.8.e038911.17","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"2025121600280921000_10.8.e038911.18","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"2025121600280921000_10.8.e038911.19","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/26.5.353"},{"key":"2025121600280921000_10.8.e038911.20","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20844"},{"key":"2025121600280921000_10.8.e038911.21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1517\/14656560903493460","article-title":"Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid","volume":"11","author":"Abbas","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"2025121600280921000_10.8.e038911.22","doi-asserted-by":"crossref","first-page":"247.e9","DOI":"10.1016\/j.neurobiolaging.2017.05.009","article-title":"NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases","volume":"57","author":"Blauwendraat","year":"2017","journal-title":"Neurobiol Aging"},{"key":"2025121600280921000_10.8.e038911.23","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1212\/WNL.0000000000002437","article-title":"Development and external validation of a prognostic model in newly diagnosed Parkinson disease","volume":"86","author":"Velseboer","year":"2016","journal-title":"Neurology"},{"key":"2025121600280921000_10.8.e038911.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.10.006"},{"key":"2025121600280921000_10.8.e038911.25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mdc3.12553","article-title":"Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson's progression markers initiative cohort","volume":"5","author":"Holden","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"2025121600280921000_10.8.e038911.26","doi-asserted-by":"publisher","DOI":"10.1177\/0891988715606232"},{"key":"2025121600280921000_10.8.e038911.27","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23429"},{"key":"2025121600280921000_10.8.e038911.28","doi-asserted-by":"publisher","DOI":"10.1042\/bj2290141"},{"key":"2025121600280921000_10.8.e038911.29","first-page":"283","article-title":"Image-selected in vivo spectroscopy (Isis). A new technique for spatially selective NMR spectroscopy","volume":"66","author":"Ordidge","year":"1986","journal-title":"J Magn Reson"},{"key":"2025121600280921000_10.8.e038911.30","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.1910080309"},{"key":"2025121600280921000_10.8.e038911.31","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp293"},{"key":"2025121600280921000_10.8.e038911.32","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.2.340"},{"key":"2025121600280921000_10.8.e038911.33","doi-asserted-by":"publisher","DOI":"10.1006\/jmre.1997.1244"},{"key":"2025121600280921000_10.8.e038911.34","doi-asserted-by":"publisher","DOI":"10.1088\/0957-0233\/20\/10\/104035"},{"key":"2025121600280921000_10.8.e038911.35","doi-asserted-by":"publisher","DOI":"10.1007\/BF02668096"},{"key":"2025121600280921000_10.8.e038911.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1991.tb01616.x"},{"key":"2025121600280921000_10.8.e038911.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151881","article-title":"Intra-rater, inter-rater and test-retest reliability of an instrumented timed up and go (iTUG) test in patients with Parkinson's disease","volume":"11","author":"van Lummel","year":"2016","journal-title":"PLoS One"},{"key":"2025121600280921000_10.8.e038911.38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.gaitpost.2018.06.166","article-title":"Upper body accelerations as a biomarker of gait impairment in the early stages of Parkinson's disease","volume":"71","author":"Buckley","year":"2019","journal-title":"Gait Posture"},{"key":"2025121600280921000_10.8.e038911.39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1109\/OJEMB.2020.2966295","article-title":"Accelerometry-based digital gait characteristics for classification of Parkinson's disease: what counts?","volume":"1","author":"Rehman","year":"2020","journal-title":"IEEE Open J Eng Med Biol"},{"key":"2025121600280921000_10.8.e038911.40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/mds.26718","article-title":"Free-living monitoring of Parkinson's disease: lessons from the field","volume":"31","author":"Del Din","year":"2016","journal-title":"Mov Disord"},{"key":"2025121600280921000_10.8.e038911.41","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9020034","article-title":"The role of movement analysis in diagnosing and monitoring neurodegenerative conditions: insights from gait and postural control","volume":"9","author":"Buckley","year":"2019","journal-title":"Brain Sci"},{"key":"2025121600280921000_10.8.e038911.42","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ff9685"},{"key":"2025121600280921000_10.8.e038911.43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf3634"},{"key":"2025121600280921000_10.8.e038911.44","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/jcph.1575","article-title":"Pharmacokinetics, safety, and tolerability of orally administered ursodeoxycholic acid in patients with Parkinson's Disease-A pilot study","volume":"60","author":"Sathe","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2025121600280921000_10.8.e038911.45","doi-asserted-by":"publisher","DOI":"10.1177\/1545968311424869"},{"key":"2025121600280921000_10.8.e038911.46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.gaitpost.2016.11.024","article-title":"A model of free-living gait: a factor analysis in Parkinson's disease","volume":"52","author":"Morris","year":"2017","journal-title":"Gait Posture"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-038911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:28:20Z","timestamp":1765873700000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-038911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,5]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjopen-2020-038911"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-038911","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}